AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11301406 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone plus amikacin for 2 days more followed by cefixime 8 mg/kg/day p.o. every 24 hours for 4 additional days
Number of subjects: 87
Study 9253549 — intervention group
Group type: EXPERIMENTAL
Intervention: West Indian infants
Number of subjects: 27459
Study 9253549 — intervention group
Group type: EXPERIMENTAL
Intervention: African infants
Number of subjects: 27459
Study 9253549 — intervention group
Group type: COMPARATOR
Intervention: European white infants
Number of subjects: 27459
Study 8275912 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg o.d.)
Number of subjects: 83
Study 8275912 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (increasing from 20 mg o.d. to 20 mg tds)
Number of subjects: 83
Study 8275912 — intervention group
Group type: COMPARATOR
Intervention: Placebo (used to maintain blinding)
Number of subjects: 83
Study 3541622 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of percutaneous estradiol
Number of subjects: 57
Study 3541622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 30563538 — intervention group
Group type: EXPERIMENTAL
Intervention: βA (2.4 g·d-1, βA1)
Number of subjects: 27
Study 30563538 — intervention group
Group type: COMPARATOR
Intervention: Matched total βA (4.8 g on alternate days, βA2)
Number of subjects: 27
Study 30563538 — intervention group
Group type: COMPARATOR
Intervention: Cornflour placebo (2.4 g·d-1, PL)
Number of subjects: 27
Study 28247635 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic therapy combined with 10 treatment sessions of hypercapnic hypoxia using a respiratory device
Number of subjects: 37
Study 28247635 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 37
Study 25914475 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol-melitracen plus omeprazole (Group 1)
Number of subjects: 262
Study 25914475 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol-melitracen plus omeprazole (Group 2)
Number of subjects: 262
Study 25914475 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol-melitracen plus omeprazole (Group 3)
Number of subjects: 262
Study 25914475 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone (Group 4)
Number of subjects: 262
Study 22392419 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation Management Service (AMS)
Number of subjects: 62
Study 22392419 — intervention group
Group type: COMPARATOR
Intervention: Primary Care Physician (PCP)
Number of subjects: 62
Study 22392419 — intervention group
Group type: COMPARATOR
Intervention: Both groups (AMS and PCP)
Number of subjects: 62
Study 20494332 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy with mesh
Number of subjects: 202
Study 20494332 — intervention group
Group type: COMPARATOR
Intervention: Anterior colporrhaphy without mesh (control group)
Number of subjects: 202
Study 20494332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh group
Number of subjects: 202
Study 20494332 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 202
Study 18378994 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multidisciplinary diagnostic facility
Number of subjects: 230
Study 18378994 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 230
Study 15832577 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-CT analysis of cancellous bone fragments from distal radius fracture zones in osteoporosis
Number of subjects: 0
Study 15832577 — intervention group
Group type: COMPARATOR
Intervention: Micro-CT analysis of cancellous bone fragments from distal radius fracture zones in non-osteoporotic patients
Number of subjects: 0
Study 12435256 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - 0.625 mg/d of conjugated equine estrogen (plus 2.5 mg/d of medroxyprogesterone acetate for women who had not had a hysterectomy)
Number of subjects: 423
Study 12435256 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins - 400 IU of vitamin E twice daily plus 500 mg of vitamin C twice daily
Number of subjects: 423
Study 12435256 — intervention group
Group type: COMPARATOR
Intervention: HRT placebo
Number of subjects: 423
Study 12435256 — intervention group
Group type: COMPARATOR
Intervention: Vitamin placebo
Number of subjects: 423
Study 12435256 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outcomes for HRT
Number of subjects: 423
Study 12435256 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outcomes for vitamins
Number of subjects: 423
Study 10601537 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat enteral nutrition (67% of non-protein energy intake)
Number of subjects: 8
Study 10601537 — intervention group
Group type: COMPARATOR
Intervention: Normal fat enteral nutrition (40% of non-protein energy intake)
Number of subjects: 8
Study 7851545 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 (rIL-2)
Number of subjects: 18
Study 7851545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1779605 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy
Number of subjects: 51
Study 1779605 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 51
Study 7025877 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 60 microgram kg‐1 and nitrous oxide in oxygen
Number of subjects: 20
Study 7025877 — intervention group
Group type: COMPARATOR
Intervention: Etomidate 0.3 mgkg‐1 and nitrous oxide in oxygen plus halothane
Number of subjects: 20
Study 31889671 — intervention group
Group type: EXPERIMENTAL
Intervention: Short anaesthetic‐ECT time interval
Number of subjects: 54
Study 31889671 — intervention group
Group type: EXPERIMENTAL
Intervention: Long anaesthetic‐ECT time interval
Number of subjects: 54
Study 31889671 — intervention group
Group type: COMPARATOR
Intervention: Normal ventilation during anaesthetic induction
Number of subjects: 54
Study 31889671 — intervention group
Group type: COMPARATOR
Intervention: Hyperventilation during anaesthetic induction
Number of subjects: 54
Study 30945297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate seed oil (PSO) - 1 g daily for 8 weeks
Number of subjects: 52
Study 30945297 — intervention group
Group type: COMPARATOR
Intervention: Placebo (paraffin) - same amounts as PSO
Number of subjects: 52
Study 27569662 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pre-operative inspiratory muscle training programme
Number of subjects: 235
Study 27569662 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 235
Study 25134043 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual Motives for Drinking (SMDs) measure
Number of subjects: 0
Study 23931458 — intervention group
Group type: EXPERIMENTAL
Intervention: Image agreement assessment using ClearCanvas™ by three fellowship‐trained specialists in uveitis.
Number of subjects: 0
Study 23931458 — intervention group
Group type: EXPERIMENTAL
Intervention: Image agreement assessment among the three reviewers.
Number of subjects: 0
Study 21544980 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF) administration
Number of subjects: 0
Study 21544980 — intervention group
Group type: COMPARATOR
Intervention: Control group (children with inflammatory state)
Number of subjects: 0
Study 21544980 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 0
Study 19178619 — intervention group
Group type: COMPARATOR
Intervention: Coping (alumina-supported) margins
Number of subjects: 16
Study 19178619 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcelain-butt (all-porcelain) margins
Number of subjects: 16
Study 19178619 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of coping and porcelain-butt margins
Number of subjects: 16
Study 17446439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) - upper limb ischemia (cuff inflation of over 200 mm Hg for 5 minutes) 6 times a day for 1 month
Number of subjects: 30
Study 17446439 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 17446439 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-L-arginine (nitric oxide synthase inhibitor)
Number of subjects: 30
Study 17446439 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral arms of subjects that received the IPC stimulus
Number of subjects: 30
Study 15121945 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg of zinc sulfate daily)
Number of subjects: 200
Study 15121945 — intervention group
Group type: COMPARATOR
Intervention: Control group (micronutrient mix without zinc)
Number of subjects: 200
Study 12516191 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzylpenicillin (1.0 g four times daily, i/v) combined with ciprofloxacin (0.5 g twice daily, per os)
Number of subjects: 40
Study 12516191 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (0.5 g twice daily, per os)
Number of subjects: 40
Study 9695301 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin G (BPG) prophylaxis every 3 weeks as a single intramuscular injection of 1.2 million units for children over 27 kg, and a half dose for those 27 kg or less.
Number of subjects: 160
Study 9695301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BPG prophylaxis).
Number of subjects: 160
Study 9695301 — intervention group
Group type: EXPERIMENTAL
Intervention: BPG prophylaxis.
Number of subjects: 160
Study 7857351 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod 800 mg/die for 60 days
Number of subjects: 181
Study 7857351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 2751741 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid (Trigastril) with 50 mg pirenzepine
Number of subjects: 10
Study 2751741 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel with 50 mg pirenzepine
Number of subjects: 10
Study 797592 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate cream (Diprosone)
Number of subjects: 60
Study 797592 — intervention group
Group type: COMPARATOR
Intervention: Locacorten 0.02% cream
Number of subjects: 60
Study 31478335 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemigliptin 50 mg once daily
Number of subjects: 283
Study 31478335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 31347742 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure Small Jaw (LSJ)
Number of subjects: 420
Study 31347742 — intervention group
Group type: COMPARATOR
Intervention: Clamp-and-tie technique (C)
Number of subjects: 420
Study 28985799 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented reality simulator training (Group 2)
Number of subjects: 28
Study 28985799 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching (Group 1)
Number of subjects: 28
Study 28985799 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional teaching (Group 1) after AR training
Number of subjects: 28
Study 25178520 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term group psychotherapy (LTG) - 80 weekly sessions of 90 min each
Number of subjects: 167
Study 25178520 — intervention group
Group type: COMPARATOR
Intervention: Short-term group psychotherapy (STG) - 20 weekly sessions of 90 min each
Number of subjects: 167
Study 23434621 — intervention group
Group type: EXPERIMENTAL
Intervention: Advisa MRI pacing system
Number of subjects: 263
Study 21453230 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free regimen (tacrolimus, mycophenolate mofetil, steroids for only 3 days)
Number of subjects: 100
Study 21453230 — intervention group
Group type: COMPARATOR
Intervention: Steroid-maintenance regimen (tacrolimus, mycophenolate mofetil, steroids on a maintenance basis)
Number of subjects: 100
Study 18079005 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritonsillar injection of tramadol (2 mg/kg)
Number of subjects: 45
Study 18079005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular analgesia with tramadol (2 mg/kg)
Number of subjects: 45
Study 18079005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15922513 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect word prime
Number of subjects: 0
Study 15922513 — intervention group
Group type: COMPARATOR
Intervention: Positive word prime
Number of subjects: 0
Study 15922513 — intervention group
Group type: COMPARATOR
Intervention: Neutral word prime
Number of subjects: 0
Study 12829675 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 200 mg/m2 every 8 hours for five doses
Number of subjects: 181
Study 12829675 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 200 mg/m2 daily for days 1 to 5 plus interferon alfa‐2b 5 MU subcutaneously three times a week
Number of subjects: 181
Study 12829675 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 150 mg/m2 (increased after one cycle to 200 mg/m2) daily on days 1 to 5 plus thalidomide 100 mg daily days 1 to 28
Number of subjects: 181
Study 11205963 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 19
Study 11205963 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 19
Study 11205963 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 19
Study 8804096 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular (collinear) triplets
Number of subjects: 0
Study 8804096 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic (not regular) triplets
Number of subjects: 0
Study 1466441 — intervention group
Group type: EXPERIMENTAL
Intervention: Hudson mask (48 l.min‐1)
Number of subjects: 138
Study 1466441 — intervention group
Group type: COMPARATOR
Intervention: Magill system (100 ml.kg‐1.min‐1)
Number of subjects: 138
Study 6689974 — intervention group
Group type: EXPERIMENTAL
Intervention: dextran 70
Number of subjects: 116
Study 6689974 — intervention group
Group type: COMPARATOR
Intervention: low-dose heparin combined with dihydroergotamine (HDHE)
Number of subjects: 116
Study 27898516 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfilcon A soft toric lens for two weeks, then LRGP lenses (Boston XO, 14.3 mm diameter)
Number of subjects: 36
Study 27898516 — intervention group
Group type: COMPARATOR
Intervention: LRGP lenses (Boston XO, 14.3 mm diameter) for two weeks, then Comfilcon A soft toric lens
Number of subjects: 36
Study 27898516 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lens types (soft toric and LRGP)
Number of subjects: 36
Study 27898516 — intervention group
Group type: EXPERIMENTAL
Intervention: LRGP lenses
Number of subjects: 36
Study 26490089 — intervention group
Group type: EXPERIMENTAL
Intervention: benidipine-thiazide
Number of subjects: 2983
Study 26490089 — intervention group
Group type: COMPARATOR
Intervention: benidipine-β-blocker
Number of subjects: 2983
Study 26490089 — intervention group
Group type: COMPARATOR
Intervention: benidipine-ARB
Number of subjects: 2983
Study 25241527 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive thoracic surgery
Number of subjects: 75
Study 25241527 — intervention group
Group type: COMPARATOR
Intervention: Conventional thoracotomy
Number of subjects: 75
Study 22653220 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 13901
Study 22653220 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13901
Study 22653220 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-high tertile
Number of subjects: 13901
Study 22653220 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA tertiles
Number of subjects: 13901
Study 19496972 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin for 6 months
Number of subjects: 42
Study 19496972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 18519478 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-results condition (pediatricians received screening results just before encounters)
Number of subjects: 878
Study 18519478 — intervention group
Group type: COMPARATOR
Intervention: Delayed-results condition (pediatricians received screening results 2 to 3 business days later)
Number of subjects: 878
Study 15851888 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve block anesthesia (0.75% ropivacaine)
Number of subjects: 50
Study 15851888 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (fast‐track general anesthesia followed by bupivacaine (0.25%) wound infiltration)
Number of subjects: 50
Study 14636900 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine echocardiography (up to 10 microg/kg/min)
Number of subjects: 425
Study 11027441 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 10 sunscreen
Number of subjects: 58
Study 11027441 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 30 sunscreen
Number of subjects: 58
Study 9056614 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg for 15 days)
Number of subjects: 24
Study 9056614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8365524 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (25 mg b.i.d.) during cycle days 16-24 for 10 months
Number of subjects: 135
Study 8365524 — intervention group
Group type: COMPARATOR
Intervention: Placebo during cycle days 16-24 for 10 months
Number of subjects: 135
Study 8365524 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (25 mg b.i.d.)
Number of subjects: 135
Study 8365524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 3805300 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress inoculation therapy
Number of subjects: 26
Study 3805300 — intervention group
Group type: COMPARATOR
Intervention: Medication therapy
Number of subjects: 26
Study 3805300 — intervention group
Group type: COMPARATOR
Intervention: Combination of stress inoculation and medication therapy
Number of subjects: 26
Study 30197313 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lumbar plexus block (CLPB)
Number of subjects: 60
Study 30197313 — intervention group
Group type: COMPARATOR
Intervention: PCIA
Number of subjects: 60
Study 26578361 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound therapy (0.4 W/cm(2 SATA))
Number of subjects: 42
Study 26578361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound therapy (20% duty cycle, 0.08 W/cm(2 SATA))
Number of subjects: 42
Study 26578361 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound therapy (0.4 W/cm(2 SATA)) after COX inhibition (aspirin)
Number of subjects: 42
Study 26578361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound therapy (20% duty cycle, 0.08 W/cm(2 SATA)) after COX inhibition (aspirin)
Number of subjects: 42
Study 26578361 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equipment power off)
Number of subjects: 42
Study 24625149 — intervention group
Group type: EXPERIMENTAL
Intervention: Enclosed tobacco display
Number of subjects: 1216
Study 24625149 — intervention group
Group type: COMPARATOR
Intervention: Warning sign (present vs absent)
Number of subjects: 1216
Study 22654944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (15 manualized sessions over 5 weeks of cognitive behavioral techniques and creative expressive elements)
Number of subjects: 399
Study 22654944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 399
Study 22654944 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 399
Study 20590434 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session psychoeducative group therapy module
Number of subjects: 19
Study 20590434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19
Study 19013336 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B (L‐AmB) 3 mg/kg/day
Number of subjects: 339
Study 19013336 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (L‐AmB) 10 mg/kg/day
Number of subjects: 339
Study 15804471 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of aspirin once a day for 14 days
Number of subjects: 51
Study 15804471 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of aspirin once a day for 14 days
Number of subjects: 51
Study 15804471 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet for 14 days
Number of subjects: 51
Study 15804471 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (75 mg, 300 mg, and placebo)
Number of subjects: 51
Study 15804471 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg and 300 mg of aspirin
Number of subjects: 51
Study 12860578 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1513
Study 12860578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513
Study 12860578 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SBP
Number of subjects: 1513
Study 12860578 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline DBP
Number of subjects: 1513
Study 10375935 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador QuS
Number of subjects: 60
Study 10375935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intron A (human recombinant interferon alpha)
Number of subjects: 60
Study 10375935 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 8669517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (work site-based cancer prevention program)
Number of subjects: 28000
Study 8669517 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28000
Study 1518264 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epinephrine infusion (0.01-0.02 mg/kg) started one hour before and finished one hour after the infusion of E. coli L-asparaginase
Number of subjects: 7
Study 6472970 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal appliance with oroenteric tubes
Number of subjects: 29
Study 6472970 — intervention group
Group type: COMPARATOR
Intervention: Nasoenteric tubes (control group)
Number of subjects: 29
Study 6472970 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of feeding tubes after several days
Number of subjects: 29
Study 30296472 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating As Treatment (EAT) intervention delivered by oncology dietitians
Number of subjects: 307